Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Hub
News
Changes
Search
Log in
Get Started
INLURIYO (IMLUNESTRANT TOSYLATE) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
INLURIYO
NDA
Get alerts
IMLUNESTRANT TOSYLATE | N218881 | ELI LILLY AND CO
1 strength
2 unique patents
1 unique exclusivity
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
Approvals
Label
Products
Patent Timeline
2 unique patents, 1 exclusivity by expiration date
Active (2)
Today
Exclusivity
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
Today
10654866
Jul. 11, 2039
11117902
Jul. 11, 2039
NCE
Sep. 25, 2030
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (1)
#001 — EQ 200MG BASE
RLD
2 patents
1 exclusivity
▴
TABLET;ORAL | Approved: Sep 25, 2025
Patents (2)
Patent #
Expiration
PED
Drug Substance
Drug Product
Use Code
Delist
10654866
Jul 11, 2039
—
Yes
Yes
U-4278
TREATMENT OF ADULTS WITH ER-POSITIVE, HER2-NEGATIVE ESR1-MUTATED ADVANCED OR METASTATIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING AT LEAST ONE LINE OF ENDOCRINE THERAPY
—
11117902
Jul 11, 2039
—
Yes
Yes
U-4278
TREATMENT OF ADULTS WITH ER-POSITIVE, HER2-NEGATIVE ESR1-MUTATED ADVANCED OR METASTATIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING AT LEAST ONE LINE OF ENDOCRINE THERAPY
—
Exclusivities (1)
Code
Date
Status
NCE
Sep 25, 2030
Active